Unrealized Gain (Loss) on Investments |
Equity securities at fair value for the periods presented were comprised of the following: | | | | | | | | | | | | | | | | | | | | | | | | | | | Security Type | | Cost | | Gross Unrealized Gain | | Gross Unrealized Loss | | Fair Value | | | (In thousands) | June 30, 2022: | | | | | | | | | Equity securities - Life Sciences Portfolio (Note 3) | | $ | 44,854 | | | $ | 57,688 | | | $ | (463) | | | $ | 102,079 | | Equity securities - other common stock | | 49,421 | | | 2 | | | (25,157) | | | 24,266 | | Total | | $ | 94,275 | | | $ | 57,690 | | | $ | (25,620) | | | $ | 126,345 | | | | | | | | | | | December 31, 2021: | | | | | | | | | Equity securities - Life Sciences Portfolio (Note 3) | | $ | 56,037 | | | $ | 262,811 | | | $ | (1,488) | | | $ | 317,360 | | Equity securities - other common stock | | 43,822 | | | 2,068 | | | (1,472) | | | 44,418 | | Total | | $ | 99,859 | | | $ | 264,879 | | | $ | (2,960) | | | $ | 361,778 | |
The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the consolidated statements of operations: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2022 | | 2021 | | 2022 | | 2021 | | (In thousands) | Change in fair value of equity securities of public companies | $ | (32,458) | | | $ | (35,057) | | | $ | (204,098) | | | $ | (29,683) | | Change in fair value of equity securities without readily determinable fair value | — | | | 46,154 | | | — | | | 77,956 | | | | | | | | | | Gain on sale of equity securities of public companies | 5,217 | | | 15,055 | | | 64,705 | | | 15,055 | | | | | | | | | | | | | | | | | | Net realized and unrealized (loss) gain | $ | (27,241) | | | $ | 26,152 | | | $ | (139,393) | | | $ | 63,328 | |
|